Project Grant F31DA062446

Award Date 6/17/25
Completion Date 12/31/26
Dollars Obligated $85K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This $373,300 Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to investigate the role of the nucleus accumbens (NAc) in learning and responding to reward-predictive cues. The research aims to enhance understanding of the neural activity dynamics in NAc that contribute to selective conditioned responses to reward-paired cues versus neutral cues. Using an auditory Pavlovian...
The National Institute of Mental Health (NIMH) awarded a $459,613 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Research Foundation For Mental Hygiene, Inc. (RFMH) to study the use of molecules that inhibit the degradation of endogenous enkephalins (a class of opioid peptides) as a potential treatment for reversing reward processing deficits associated with psychiatric disorders like major depressive disorder and schizophrenia. The project aims to administer these...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the "need-state hypothesis" in cocaine addiction. The $685,856 award to Pennsylvania State University, specifically the Penn State Milton S. Hershey Medical Center, aims to use an animal model to identify early indicators of addiction vulnerability and test whether a glucagon-like peptide-1 (GLP-1)...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $242,310 in funding to The Medical College of Wisconsin, Inc. to conduct research on the involvement of GQ signaling in the mobilization of 2-arachidonoylglycerol (2-AG) by corticosterone in the prefrontal cortex, and its potential impact on stress-related relapse in substance use disorder. The research aims to enhance understanding of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to determine how specific neurological markers can predict responses to repetitive transcranial magnetic stimulation (rTMS) treatments for substance use disorders (SUDs). The $816,604 award will be used to identify neuromarkers of reward reactivity and cognitive control that moderate the effectiveness of rTMS interventions targeting the...
The federal Project Grant award R01DA061766 for $428,194.00, awarded on April 1, 2025 by the National Institute on Drug Abuse (NIDA), supports research to understand the role of prefrontal cortex circuits in controlling heroin-seeking behavior. The primary goal is to determine whether the recruitment of an infralimbic (IL) cortex driver circuit is a hallmark of heroin-induced pathology, whether this IL subcircuit engages a positive feedback loop via the orexin system to perpetuate heroin...
The National Institute of Mental Health (NIMH) awarded a $624,368 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, San Diego (UCSD) to optimize, pharmacologically test, and mechanistically probe a novel in-vivo behavioral and neurophysiological assay for studying risk-taking propensity. The goal is to establish this assay as a translational tool for screening novel drugs to treat psychiatric conditions associated with high or low risk aversion, such as...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $206,875 to the Research Foundation For Mental Hygiene, Inc. (RFMH) to investigate the impact of GRIN2B/GLUN2B disruption on dopaminergic function and related behavior. The project aims to use a conditional Cre/Lox strategy in mice to assess the effects of diminished GLUN2B signaling on dopaminergic neuron firing, dopamine release, and downstream...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $149,284 to the University of Washington to investigate the role of prefrontal cortex pyramidal neuron subpopulations in regulating drug-seeking behavior. The research will use fiber photometry and chemogenetic techniques to characterize alterations to intratelencephalic (IT) and pyramidal tract (PT) neuron activity in the prelimbic region of the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating a specialized serotonergic-septohippocampal circuit that may influence the vulnerability for relapse in substance use disorders. The $254,250 award, spanning from July 2024 to June 2026, will support the delineation of the intrinsic properties and transmission interactions of a novel neuronal cell type (LSI-R2P) that is modulated...

THE GLUCOCORTICOID RECEPTOR AS A TOP-DOWN NEUROMOLECULAR MECHANISM OF INHIBITORY CONTROL - ABSTRACT ENVIRONMENTAL STIMULI, OR CUES, CAN ELICIT MALADAPTIVE BEHAVIOR. THIS IS PARTICULARLY OBSERVED IN THOSE WITH PSYCHIATRIC DISORDERS LIKE SUBSTANCE USE DISORDER (SUD), WHERE A CUE THAT IS ASSOCIATED WITH PRIOR DRUG USE (E.G. PARAPHERNALIA), CAN RESULT IN RELAPSE REGARDLESS OF THE INDIVIDUAL'S DESIRE TO REMAIN ABSTINENT. SUCH CUE- MOTIVATED BEHAVIORS ARE A RESULT OF BEHAVIORAL DISINHIBITION, OR A LACK OF INHIBITORY CONTROL. DEFICITS IN INHIBITORY CONTROL ARE BROADLY REFERRED TO AS "IMPULSIVITY", A TERM FURTHER DEFINED BY 1) HEIGHTENEDkRESPONSIVENESS TO REWARD-ASSOCIATED CUES (I.E., REWARD SENSITIVITY) AND 2) IMPULSIVE ACTIONS CONDUCTED WITHOUT REGARD TO RISK OR CONSEQUENCES (I.E., RASH IMPULSIVITY). STUDIES IN HUMANS AND RODENTS SHOW THAT INDIVIDUALS WITH HEIGHTED REWARD SENSITIVITY ALSO EXHIBIT INCREASED RASH IMPULSIVITY. BOTH FACETS OF IMPULSIVITY CONTRIBUTE TO MALADAPTIVE BEHAVIORS, YET THE NEURAL UNDERPINNINGS OF THESE PROCESSES REMAIN ELUSIVE. AN OVERARCHING GOAL OF THIS PROPOSAL IS TO DETERMINE WHETHER BOTH FACETS OF IMPULSIVITY SHARE THE SAME NEURAL MECHANISM. SPECIFICALLY, THIS RESEARCH FOCUSES ON A TOP-DOWN INHIBITORY CONTROL PATHWAY: THE PRELIMBIC CORTEX (PRL) TO THE NUCLEUS ACCUMBENS CORE (NACC). GLUTAMATERGIC PROJECTIONS FROM THE PRL TO THE NACC HAVE BEEN SHOWN TO MODULATE REWARD-SEEKING BEHAVIOR AND REGULATE NACC DOPAMINE (DA) ACTIVITY. DA SIGNALING IN THE NACC ALSO UNDERLIES IMPULSIVE ACTION (RASH IMPULSIVITY) AND THE ATTRIBUTION OF INCENTIVE MOTIVATIONAL VALUE, OR SALIENCE, TO A REWARD CUE (REWARD SENSITIVITY). HOWEVER, THE MECHANISM BY WHICH THESE INTERACTIONS OCCUR WITHIN THIS PATHWAY IS UNCLEAR. THE PROPOSED RESEARCH WILL INVESTIGATE THE GLUCOCORTICOID RECEPTOR (GR) AS A NEUROMOLECULAR MECHANISM WITHIN THE PRL-NACC PATHWAY THAT REGULATES REWARD SENSITIVITY AND RASH IMPULSIVITY VIA ITS EFFECTS ON NACC DA SIGNALING. WHILE THE GR IS KNOWN AS A PRIMARY REGULATOR OF STRESS RESPONSIVITY, IT ALSO REGULATES NACC DA AND PLAYS A ROLE IN REWARD-RELATED BEHAVIORS, INCLUDING REWARD SENSITIVITY. IN ADDITION, GR HAS BEEN IMPLICATED IN PSYCHIATRIC CONDITIONS CHARACTERIZED BY BEHAVIORAL DISINHIBITION. TO EXAMINE THE ROLE OF GR IN INHIBITORY CONTROL PROCESSES, TRANSGENIC RATS WITH CONDITIONAL GR KNOCKDOWN ALLELES WILL BE EMPLOYED TO SELECTIVELY KNOCK DOWN GR IN PRL-NACC PROJECTION NEURONS. AIM 1 WILL ASSESS THE EFFECTS OF THIS MANIPULATION ON REWARD SENSITIVITY USING A PAVLOVIAN CONDITIONED APPROACH PARADIGM THAT CAPTURES VARIABILITY IN THE ATTRIBUTION OF INCENTIVE SALIENCE TO A REWARD CUE. AIM 2 WILL ASSESS THE EFFECTS OF GR KNOCKDOWN ON RASH IMPULSIVITY USING A GO/NO-GO PARADIGM TO MEASURE THE INABILITY TO WITHHOLD BEHAVIOR IN RESPONSE TO A CUE. FOR BOTH AIMS, FAST-SCAN CYCLIC VOLTAMMETRY (FSCV) WILL BE USED TO MEASURE DA SIGNALING WITHIN THE NACC IN RESPONSE TO THE REWARD-ASSOCIATED CUE (AIM 1) AND THE "GO-" AND "NO-GO" CUES (AIM 2). THIS RESEARCH HAS THE POTENTIAL TO UNCOVER A NEUROMOLECULAR MECHANISM OF INHIBITORY CONTROL AND, IN TURN, LEAD TO BETTER TREATMENTS FOR PSYCHIATRIC DISORDERS CHARACTERIZED BY DYSFUNCTIONAL IMPULSIVITY.

Posted 12/17/24, 12:00 AM